On the Case: An Expert Panel Challenge for the Management of Difficult Cases of CRSwNP

Sniff out these challenging cases with faculty!

Sunday, September 11, 2022

Registration & Lunch: 11:00 AM – 11:45 AM EDT
Presentation: 11:45 AM – 12:45 PM EDT

VENUE

Commonwealth Hall CD / Second Floor
Loews
Philadelphia Hotel
1200 Market Street
Philadelphia, Pennsylvania 1910
7

PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

This commercially supported Product Theater is independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and is not accredited by AAOA.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

PROGRAM OVERVIEW

The emergence of biologics for chronic rhinosinusitis with nasal polyps (CRSwNP) has provided clinicians with a new option in the management of patients with CRSwNP. Identifying the role of these agents, how they fit in with surgery and standard treatments, and in which patient populations these therapies might be preferred are some of the many issues that challenge clinicians in patient management. This activity will review the most recent recommendations for treatment selection, current evidence for the use of biologics in practice, and key updates to support patient care delivery. Clinical evidence will be supported by interactive patient case review, interactive polling, and expert panel discussion. Follow the unrehearsed decision-making by faculty members and see if you sniff out the same conclusions!

TARGET AUDIENCE

This program is intended for otolaryngologists and otolaryngic allergists, as well as nurse practitioners and physician assistants in otolaryngology specialty practice.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Differentiate between each new and emerging biologic treatment for CRSwNP using data from clinical trials and other analyses
  • Incorporate a patient-centric focus into evaluating the physical, extranasal, and psychosocial aspects of disease burden for each CRSwNP patient
  • Elucidate best practices criteria for recommending sinus surgery or biologic therapy and when systemic corticosteroids may or may not be appropriate

FACULTY PANEL

Joseph K. Han, MD (Moderator)
Professor of Medicine
Chief, Division of Rhinology & Endoscopic
Sinus and Skull Base Surgery
Eastern Virginia Medical School
Norfolk, Virginia

Anju T. Peters, MD
Professor of Medicine
Director of Clinical Research
Division of Allergy/Immunology and Otolaryngology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Bruce K. Tan, MD
Associate Professor of Medicine
Otolaryngology – Head and Neck Surgery
Northwestern University Feinberg School of Medicine
Chicago, Illinois

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

FEE INFORMATION

There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We do recommend arriving at the satellite symposium location early.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Integrity Continuing Education, Inc. prior to the live event at (855) 835-4004.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Joseph K. Han, MD
Consulting Fees: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Anju T. Peters, MD
Consultant: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron
Research grant (to institution): Optinose, Sanofi Regeneron

Bruce K. Tan, MD
Will be provided at the live event

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Agenda

Date: Sunday, September 11, 2022

Location:
Commonwealth Hall CD / Second Floor
Loews Philadelphia Hotel
1200 Market Street
Philadelphia, Pennsylvania 19107

11:00 AM – 11:45 AM EDT Registration & Lunch
11:45 AM – 12:30 PM EDT Case-based Discussion and Lecture Topics Include:

  • Understanding the Disease Burden of CRSwNP
  • Pathogenetics and Molecular Drivers
  • Medical Management
  • Biologic Treatments
  • Surgical Treatment
  • Ascertaining the Role of Surgery and OCS with biologics
12:30 PM – 12:45 PM EDT Summary, Conclusions, and Questions and Answers

 

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME creditTM. To do so, you must participate in the live program and complete the posttest and evaluation following the event. A statement of credit will be issued within 3 weeks of submission of a completed activity evaluation form.